Jianan Sui , Weirong Cui , Xiaoxiao Zhang , Hongliang Duan , Jingjing Guo
{"title":"Human miRNA–disease Association Prediction Via Residual GraphSAGE With Nonlinear Adaptive Feature Fusion and Triplet Contrastive Learning","authors":"Jianan Sui , Weirong Cui , Xiaoxiao Zhang , Hongliang Duan , Jingjing Guo","doi":"10.1016/j.jmb.2025.169360","DOIUrl":null,"url":null,"abstract":"<div><div>MicroRNAs (miRNAs) play pivotal roles in cellular regulation, and their dysregulation is closely linked to a wide spectrum of human diseases; thus, accurate miRNA–disease association prediction is critical for guiding experimental validation and therapeutic development. In this work, we propose RGFMDA, an innovative framework designed to predict miRNA-disease associations more effectively. RGFMDA employs a residual graph sampling and aggregation network to enhance information localization within miRNA and disease networks. It also features a nonlinear integration of features and a global context integration module that synergistically combine feature interactions and oversee global dependencies. Additionally, the framework uses triplet contrastive learning to refine the distinction between associated and non-associated miRNA-disease pairs, enhancing the accuracy of predictions. On the HMDD v2.0 benchmark, RGFMDA achieved an AUC of 0.9524, surpassing existing approaches whose reported AUC values range from approximately 0.916 to 0.942. On the HMDD v3.2 dataset, RGFMDA further improved performance with an AUC of 0.9604, exceeding state-of-the-art models that demonstrate AUCs between roughly 0.912 and 0.953. Case studies involving lung, esophageal, breast, and colorectal cancers have further confirmed the efficacy of RGFMDA. In summary, RGFMDA represents a robust and reliable computational tool for uncovering novel miRNA–disease associations, thereby facilitating future biological discovery and therapeutic development.</div></div>","PeriodicalId":369,"journal":{"name":"Journal of Molecular Biology","volume":"437 19","pages":"Article 169360"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Biology","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022283625004267","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
MicroRNAs (miRNAs) play pivotal roles in cellular regulation, and their dysregulation is closely linked to a wide spectrum of human diseases; thus, accurate miRNA–disease association prediction is critical for guiding experimental validation and therapeutic development. In this work, we propose RGFMDA, an innovative framework designed to predict miRNA-disease associations more effectively. RGFMDA employs a residual graph sampling and aggregation network to enhance information localization within miRNA and disease networks. It also features a nonlinear integration of features and a global context integration module that synergistically combine feature interactions and oversee global dependencies. Additionally, the framework uses triplet contrastive learning to refine the distinction between associated and non-associated miRNA-disease pairs, enhancing the accuracy of predictions. On the HMDD v2.0 benchmark, RGFMDA achieved an AUC of 0.9524, surpassing existing approaches whose reported AUC values range from approximately 0.916 to 0.942. On the HMDD v3.2 dataset, RGFMDA further improved performance with an AUC of 0.9604, exceeding state-of-the-art models that demonstrate AUCs between roughly 0.912 and 0.953. Case studies involving lung, esophageal, breast, and colorectal cancers have further confirmed the efficacy of RGFMDA. In summary, RGFMDA represents a robust and reliable computational tool for uncovering novel miRNA–disease associations, thereby facilitating future biological discovery and therapeutic development.
期刊介绍:
Journal of Molecular Biology (JMB) provides high quality, comprehensive and broad coverage in all areas of molecular biology. The journal publishes original scientific research papers that provide mechanistic and functional insights and report a significant advance to the field. The journal encourages the submission of multidisciplinary studies that use complementary experimental and computational approaches to address challenging biological questions.
Research areas include but are not limited to: Biomolecular interactions, signaling networks, systems biology; Cell cycle, cell growth, cell differentiation; Cell death, autophagy; Cell signaling and regulation; Chemical biology; Computational biology, in combination with experimental studies; DNA replication, repair, and recombination; Development, regenerative biology, mechanistic and functional studies of stem cells; Epigenetics, chromatin structure and function; Gene expression; Membrane processes, cell surface proteins and cell-cell interactions; Methodological advances, both experimental and theoretical, including databases; Microbiology, virology, and interactions with the host or environment; Microbiota mechanistic and functional studies; Nuclear organization; Post-translational modifications, proteomics; Processing and function of biologically important macromolecules and complexes; Molecular basis of disease; RNA processing, structure and functions of non-coding RNAs, transcription; Sorting, spatiotemporal organization, trafficking; Structural biology; Synthetic biology; Translation, protein folding, chaperones, protein degradation and quality control.